Amniotic membrane is one of the few biologic materials with a long, well-documented track record in both wound care and ophthalmology. That shared history is exactly why the question comes up: if a clinician already stocks an amniotic membrane allograft for chronic wounds, can it be used on the ocular surface?
The honest answer has two parts. The ophthalmic evidence for amniotic membrane is genuinely strong and decades deep. But the ophthalmic products that evidence was built on are not the same as wound-care allografts — they are processed, sized, regulated, and delivered differently. Understanding that distinction is the difference between responsible practice and an off-label shortcut that carries real risk.
Why the Eye Was One of Amniotic Membrane's First Homes
Long before amniotic membrane became a mainstream chronic-wound therapy, ophthalmologists were using it to rebuild the ocular surface. The same biology that makes it useful on a diabetic foot ulcer applies to the cornea and conjunctiva: an intact basement membrane that mimics the surface epithelial cells need to migrate across, a concentrated payload of growth factors and anti-inflammatory mediators, and immune-privileged tissue that provokes little rejection.
On the ocular surface, those properties translate into three well-characterized effects: it promotes epithelial healing, it suppresses inflammation and scarring, and it provides a scaffold for reconstruction. For a detailed treatment of the underlying biology, see our amniotic membrane science guide.
What the Ophthalmic Evidence Actually Supports
The clinical literature on ocular amniotic membrane transplantation (AMT) spans nearly three decades and covers a range of ocular surface disease:
- Persistent epithelial defects (PED) and sterile corneal ulcers. In a foundational series, amniotic membrane transplantation healed persistent epithelial defects with ulceration that had been refractory to conventional therapy, with defects resolving over several weeks and remaining stable on follow-up (Lee & Tseng, American Journal of Ophthalmology, 1997; PMID 9063239). Later work established that single- versus multilayer technique can be matched to defect depth, including cases with stromal thinning (Prabhasawat et al., British Journal of Ophthalmology, 2001; PMID 11734521). - Defects after corneal transplantation. In eyes with persistent defects following penetrating keratoplasty, AMT achieved surgical success in a majority of eyes, though success declined with the number of previous transplants (Seitz et al., Eye (London), 2009; PMID 18535612). - Reconstructive and surgical uses. AMT is also used as a graft or patch in pterygium surgery, chemical and thermal burns, symblepharon release, and other ocular surface reconstruction, where its anti-scarring and anti-inflammatory behavior is the primary rationale.
The consistent theme is ocular surface disease — the cornea and conjunctiva — where amniotic membrane acts as a biological bandage and scaffold rather than a structural replacement.
The Product Distinction That Matters Most
Here is where the wound-care-versus-ophthalmology question becomes concrete. The ophthalmic evidence above was generated using ophthalmic-specific amniotic membrane products, not wound allografts repurposed for the eye. Those products differ on several axes that are clinically non-trivial:
- Intended use and FDA pathway. Ophthalmic amniotic membrane is delivered through products designed and regulated for ocular use — including sutureless self-retaining devices that carry 510(k) clearance for the ocular surface, and ophthalmic-grade sheet grafts. A wound-care allograft is typically regulated as a minimally manipulated human tissue (an HCT/P under Section 361) intended for homologous wound use. Using it on the eye is off-label and outside that intended use. - Sterility assurance. The eye is an immunologically and structurally unforgiving site. Ophthalmic products are processed to specifications appropriate for ocular application; a wound dressing is not validated for placement on the cornea or under the conjunctiva. - Format, thickness, and handling. Ocular application demands specific thickness, transparency, orientation, and delivery — a ring-mounted device or a thin graft handled under the operating microscope — that a wound sheet is not built for. - Orientation and technique. Ophthalmic AMT depends on correct stromal-side-versus-epithelial-side orientation and surgical fixation. This is specialist technique, not a wound-dressing application.
None of this diminishes the ophthalmic evidence. It clarifies it: the evidence supports amniotic membrane for the eye when delivered as an ophthalmic product by a trained ophthalmologist — not the substitution of a wound allograft into an indication it was never processed or cleared for.
The Responsible Read for Wound-Care Teams
For clinicians and formularies that stock amniotic membrane for wounds, the practical guidance is straightforward:
1. The ophthalmic evidence is real, but it is not a license to repurpose a wound product. A chronic-wound allograft and an ocular-surface device are different tools built for different tissues. 2. Ocular surface disease belongs with ophthalmology. Persistent epithelial defects, corneal ulcers, and surface reconstruction should be managed by an ophthalmologist using a product intended for the eye. 3. Match the product to the indication and its regulatory pathway. For wound care, that means selecting a wound allograft on the evidence for that use — see our dehydrated versus cryopreserved clinician guide — and leaving ocular indications to ophthalmic products.
Amniotic membrane's dual history in wounds and eyes is a testament to how versatile the tissue is. But versatility at the biological level does not erase the regulatory, sterility, and technique boundaries between a wound dressing and an ophthalmic device. The evidence is strong precisely because it was generated with the right product, in the right hands, for the right indication.
References
1. Lee SH, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. American Journal of Ophthalmology. 1997. PMID: 9063239. 2. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. British Journal of Ophthalmology. 2001. PMID: 11734521. 3. Seitz B, et al. Amniotic membrane transplantation for persistent corneal epithelial defects in eyes after penetrating keratoplasty. Eye (London). 2009. PMID: 18535612.